| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA854: Esketamine for treatment-resistant depression |
|
Medicine details |
|
| Medicine name | esketamine (Spravato®) |
| Formulation | 28 mg nasal spray |
| Reference number | 3089 |
| Indication | In combination with a SSRI or SNRI, for adults with treatment-resistant major depressive disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 14/11/2019 |
| NICE guidance | |